Pharmaceutical services company Open Orphan announced the signing of a new contract with Carna Bioscience on Tuesday, for a first-in-human clinical pharmacology trial. Photo: Pruebas en un laboratorio. The AIM-traded firm said the contract… read more →
Open Orphan (ORPH) Follow has inked a new contract with Carna Bioscience for a first-in-human clinical pharmacology trial, which is expected to deliver significant recurring revenue over the next year. Under the… read more →
New contract with Japanese company Carna Bioscience follows close collaboration on drug development planning and pre-clinical activities Open Orphan executive chairman Cathal Friel. Dublin-listed pharmaceutical services company Open Orphan has signed a… read more →
Open Orphan plc (“Open Orphan” or the “Company”) New Contract Win with Carna Bioscience (“Carna”) 04 August 2020 Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company… read more →
Cathal Friel, executive chairman at Open Orphan Dublin-listed pharmaceutical company Open Orphan has announced a new contract with Codagenix to conduct a first human trial evaluating safety and immunogenicity of… read more →